|
1
|
Ng SC, Shi HY, Hamidi N, Underwood FE,
Tang W, Benchimol EI, Panaccione R, Ghosh S, Wu JCY, Chan FKL, et
al: Worldwide incidence and prevalence of inflammatory bowel
disease in the 21st century: A systematic review of
population-based studies. Lancet. 390:2769–2778. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zhou M, He J, Shen Y, Zhang C, Wang J and
Chen Y: New frontiers in genetics, gut microbiota and immunity: A
Rosetta stone for the pathogenesis of inflammatory bowel disease.
Biomed Res Int. 2017:82016722017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Coskun M, Vermeire S and Nielsen OH: Novel
targeted therapies for inflammatory bowel disease. Trends Pharmacol
Sci. 38:127–142. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Münzberg H and Morrison CD: Structure,
production and signaling of leptin. Metabolism. 64:13–23. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Abella V, Scotece M, Conde J, Pino J,
Gonzalez-Gay MA, Gómez-Reino JJ, Mera A, Lago F, Gómez R and
Gualillo O: Leptin in the interplay of inflammation, metabolism and
immune system disorders. Nat Rev Rheumatol. 13:100–109. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Singh UP, Singh NP, Guan H, Busbee B,
Price RL, Taub DD, Mishra MK, Fayad R, Nagarkatti M and Nagarkatti
PS: Leptin antagonist ameliorates chronic colitis in
IL-10−/− mice. Immunobiology. 218:1439–1451.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cakir B, Bozkurt A, Ercan F and Yeğen BC:
The anti-inflammatory effect of leptin on experimental colitis:
Involvement of endogenous glucocorticoids. Peptides. 25:95–104.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bozkurt A, Cakir B, Ercan F and Yeğen BC:
Anti-inflammatory effects of leptin and cholecystokinin on acetic
acid-induced colitis in rats: Role of capsaicin-sensitive vagal
afferent fibers. Regul Pept. 116:109–118. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kahraman R, Calhan T, Sahin A, Ozdil K,
Caliskan Z, Bireller ES and Cakmakoglu B: Are adipocytokines
inflammatory or metabolic mediators in patients with inflammatory
bowel disease? Ther Clin Risk Manag. 13:1295–1301. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Trejo-Vazquez F, Garza-Veloz I,
Villela-Ramirez GA, Ortiz-Castro Y, Mauricio-Saucedo P,
Cardenas-Vargas E, Diaz-Baez M, Cid-Baez MA, Castañeda-Miranda R,
Ortiz-Rodriguez JM, et al: Positive association between leptin
serum levels and disease activity on endoscopy in inflammatory
bowel disease: A case-control study. Exp Ther Med. 15:3336–3344.
2018.PubMed/NCBI
|
|
11
|
Ghomraoui FA, Alotaibi ST, Alharthi MA,
Asiri SS, Almadi MA, Alharbi OR, Azzam NA, Aljebreen AM, Saeed M,
Hajkhder B, et al: Plasma ghrelin and leptin in patients with
inflammatory bowel disease and its association with nutritional
status. Saudi J Gastroenterol. 23:199–205. 2017.PubMed/NCBI
|
|
12
|
Nikolaus S and Schreiber S: Diagnostics of
inflammatory bowel disease. Gastroenterology. 133:1670–1689. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lin H, Honglang L, Weifeng L, Junmin C,
Jiantao Y and Junjing G: The mechanism of alopolysaccharide
protecting ulceralive colitis. Biomed Pharmacother. 88:145–150.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang J, Chen H, Wang Y, Cai X, Zou M, Xu
T, Wang M, Wang J and Xu D: Therapeutic efficacy of a mutant of
keratinocyte growth factor-2 on trinitrobenzene sulfonic
acid-induced rat model of Crohn's disease. Am J Transl Res.
8:530–543. 2016.PubMed/NCBI
|
|
15
|
Zhao HM, Wang Y, Huang XY, Huang MF, Xu R,
Yue HY, Zhou BG, Huang HY, Sun QM and Liu DY: Astragalus
polysaccharide attenuates rat experimental colitis by inducing
regulatory T cells in intestinal Peyer's patches. World J
Gastroenterol. 22:3175–3185. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lu Y, Lin H, Zhang J, Wei J, Sun J and Han
L: Sijunzi Decoction attenuates 2, 4, 6-trinitrobenzene sulfonic
acid (TNBS)-induced colitis in rats and ameliorates TNBS-induced
claudin-2 damage via NF-κB pathway in Caco2 cells. BMC Complement
Altern Med. 17:352017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Flatow EA, Komegae EN, Fonseca MT, Brito
CF, Musteata FM, Antunes-Rodrigues J and Steiner AA: Elucidating
the role of leptin in systemic inflammation: A study targeting
physiological leptin levels in rats and their macrophages. Am J
Physiol Regul Integr Comp Physiol. 313:R572–R82. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mowat C, Cole A, Windsor A, Ahmad T,
Arnott I, Driscoll R, Mitton S, Orchard T, Rutter M, Younge L, et
al: Guidelines for the management of inflammatory bowel disease in
adults. Gut. 60:571–607. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Pan WW and Myers MG Jr: Leptin and the
maintenance of elevated body weight. Nat Rev Neurosci. 19:95–105.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang B, Chandrasekera PC and Pippin JJ:
Leptin- and leptin receptor-deficient rodent models: Relevance for
human type 2 diabetes. Curr Diabetes Rev. 10:131–145. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Paik J, Fierce Y, Treuting PM, Brabb T and
Maggio-Price L: High-fat diet-induced obesity exacerbates
inflammatory bowel disease in genetically susceptible Mdr1a-/- male
mice. J Nutr. 143:1240–1247. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sun SC: The non-canonical NF-κB pathway in
immunity and inflammation. Nat Rev Immunol. 17:545–58. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Fan Y, Mao R and Yang J: NF-κB and STAT3
signaling pathways collaboratively link inflammation to cancer.
Protein Cell. 4:176–185. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hayden MS and Ghosh S: Regulation of NF-κB
by TNF family cytokines. Semin Immunol. 26:253–266. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
El-Salhy M and Umezawa K: Effects of AP-1
and NF-κB inhibitors on colonic endocrine cells in rats with
TNBS-induced colitis. Mol Med Rep. 14:1515–1522. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lee C, Kim BG, Kim JH, Chun J, Im JP and
Kim JS: Sodium butyrate inhibits the NF-kappa B signaling pathway
and histone deacetylation, and attenuates experimental colitis in
an IL-10 independent manner. Int Immunopharmacol. 51:47–56. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Segain JP, Raingeard de la Blétière D,
Sauzeau V, Bourreille A, Hilaret G, Cario-Toumaniantz C, Pacaud P,
Galmiche JP and Loirand G: Rho kinase blockade prevents
inflammation via nuclear factor kappa B inhibition: Evidence in
Crohn's disease and experimental colitis. Gastroenterology.
124:1180–1187. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zou Y, Ma L, Zhao Y, Zhang S, Zhou C and
Cai Y: Inhibition of Rho kinase protects against colitis in mice by
attenuating intestinal epithelial barrier dysfunction via MLC and
the NF-κB pathway. Int J Mol Med. 41:430–438. 2018.PubMed/NCBI
|
